Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. Thomas Wirth, senior life science executive, Mrs. Nora Kaarela, senior pharma industry and board professional and investor Mr. Silvio Inderbitzin, and early stage life sciences board professional and start-up and growth company enabler Mr. Roger Meier were duly elected to continue as board directors.
Iain brings to the company considerable experience in the Pharmaceutical and Biotech industries in both executive and non-executive roles. Most recently he served as CEO of NOXXON Pharma AG in Berlin. Prior to that, Iain was CEO of Novexel SA in Paris from its creation as the anti-infective spin out from Sanofi-Aventis in 2004 until its sale in 2009. Previously, he held a variety of management roles including a senior position with Vertex Pharmaceuticals where he was responsible for business development activities and for creating the European subsidiary. In the past he also worked for both Cilag AG (a division of Johnson and Johnson) and Biogen SA in Switzerland. Iain holds a Bachelor of Science in Physiology from the University of St. Andrews, Scotland, and currently serves as the chairman of the board for Adapsyn Bioscience Inc, a non-executive director of Synairgen Plc and a member of the advisory board of Allecra Therapeutics.
“We are delighted to welcome Iain to our board of directors,” said Juha Yrjänheikki, CEO of Aurealis Therapeutics. “His experience, breadth of knowledge, capacity for strategic thinking and connections in the biotech industry are impressive. We look forward to his contributions to the company as we are getting to the first patient trial with our chronic wound product AUP-16 and advancing the non-clinical oncology and osteoarthritis programs.”
“I am very pleased to join the Board of Aurealis Therapeutics,” said Mr. Buchanan. “I look forward to working with my colleagues and with the entire management team to bring this innovative technology into clinical development. Furthermore, I share the enthusiasm within Aurealis to exploit the therapeutic potential of its technology across a spectrum of indications”
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage biopharmaceutical company focusing on the development of the clinical asset AUP-1602, the first-in-class four-in-one combination biologic drug for chronic wounds and other chronic inflammatory and degenerative diseases. The product is based on proprietary technology where genetically engineered lactic acid bacteria act as millions of small immune activating bioreactors in the human tissue and produce multiple human therapeutic proteins into the target tissue to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Juha Yrjänheikki, CEO
Tel: +358 45 8433550